Literature DB >> 23124885

Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.

Fung Zhao1, Eric W-F Lam.   

Abstract

The forkhead transcription factors FOXO and FOXM1 have pivotal roles in tumorigenesis and in mediating chemotherapy sensitivity and resistance. Recent research shows that the forkhead transcription factor FOXM1 is a direct transcriptional target repressed by the forkhead protein FOXO3a, a vital downstream effector of the PI3K-AKT-FOXO signaling pathway. Intriguingly, FOXM1 and FOXO3a also compete for binding to the same gene targets, which have a role in chemotherapeutic drug action and sensitivity. An understanding of the role and regulation of the FOXO-FOXM1 axis will impact directly on our knowledge of chemotherapeutic drug action and resistance in patients, and provide new insights into the design of novel therapeutic strategy and reliable biomarkers for prediction of drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124885     DOI: 10.1007/s11684-012-0228-0

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  44 in total

1.  FoxM1 is required for execution of the mitotic programme and chromosome stability.

Authors:  Jamila Laoukili; Matthijs R H Kooistra; Alexandra Brás; Jos Kauw; Ron M Kerkhoven; Ashby Morrison; Hans Clevers; René H Medema
Journal:  Nat Cell Biol       Date:  2005-01-16       Impact factor: 28.824

Review 2.  The emerging roles of forkhead box (Fox) proteins in cancer.

Authors:  Stephen S Myatt; Eric W-F Lam
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

3.  The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells.

Authors:  Patricia A Madureira; Rana Varshochi; Demetra Constantinidou; Richard E Francis; R Charles Coombes; Kwok-Ming Yao; Eric W-F Lam
Journal:  J Biol Chem       Date:  2006-06-28       Impact factor: 5.157

4.  FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.

Authors:  Miranda S C Wilson; Jan J Brosens; Helma D C Schwenen; Eric W-F Lam
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

5.  Induction of human epithelial stem/progenitor expansion by FOXM1.

Authors:  Emilios Gemenetzidis; Daniela Elena-Costea; Eric K Parkinson; Ahmad Waseem; Hong Wan; Muy-Teck Teh
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

6.  FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

Authors:  Richard E Francis; Stephen S Myatt; Janna Krol; Johan Hartman; Barrie Peck; Ursula B McGovern; Jun Wang; Stephanie K Guest; Aleksandra Filipovic; Ondrej Gojis; Carlo Palmieri; David Peston; Sami Shousha; Qunyan Yu; Piotr Sicinski; R Charles Coombes; Eric W-F Lam
Journal:  Int J Oncol       Date:  2009-07       Impact factor: 5.650

7.  Resist or die: FOXO transcription factors determine the cellular response to chemotherapy.

Authors:  Ana R Gomes; Jan J Brosens; Eric W-F Lam
Journal:  Cell Cycle       Date:  2008-10-05       Impact factor: 4.534

8.  The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells.

Authors:  Janna Krol; Richard E Francis; André Albergaria; Andrew Sunters; Andreas Polychronis; R Charles Coombes; Eric W-F Lam
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

9.  FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.

Authors:  Andrew Sunters; Silvia Fernández de Mattos; Marie Stahl; Jan J Brosens; Georgia Zoumpoulidou; Catherine A Saunders; Paul J Coffer; René H Medema; R Charles Coombes; Eric W-F Lam
Journal:  J Biol Chem       Date:  2003-10-03       Impact factor: 5.157

10.  FOXO transcription factors: key regulators of cell fate.

Authors:  E W-F Lam; R E Francis; M Petkovic
Journal:  Biochem Soc Trans       Date:  2006-11       Impact factor: 5.407

View more
  29 in total

Review 1.  Targeting forkhead box M1 transcription factor in breast cancer.

Authors:  Ruth M O'Regan; Rita Nahta
Journal:  Biochem Pharmacol       Date:  2018-05-31       Impact factor: 5.858

2.  Tight correlation between FoxM1 and FoxP3+ Tregs in gastric cancer and their clinical significance.

Authors:  Xiaoxiao Li; Kai Ma; Shanai Song; Fangzhen Shen; Tao Kuang; Yingqian Zhu; Zimin Liu
Journal:  Clin Exp Med       Date:  2018-05-26       Impact factor: 3.984

3.  Resistance to HER2-targeted therapies: a potential role for FOXM1.

Authors:  Bridgette F Peake; Rita Nahta
Journal:  Breast Cancer Manag       Date:  2014

4.  MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.

Authors:  S S Gayle; R C Castellino; M C Buss; R Nahta
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment.

Authors:  Lidia Santos Silva; Luis Gafeira Goncalves; Fernanda Silva; Germana Domingues; Valdemar Maximo; Joana Ferreira; Eric W-F Lam; Sergio Dias; Ana Felix; Jacinta Serpa
Journal:  Tumour Biol       Date:  2015-11-12

6.  Sophoridine suppresses cell growth in human medulloblastoma through FoxM1, NF-κB and AP-1.

Authors:  Zhensong Yue; Tongguo Si; Zhanyu Pan; Wenfeng Cao; Zhuchen Yan; Zhansheng Jiang; Huaqiang Ouyang
Journal:  Oncol Lett       Date:  2017-10-19       Impact factor: 2.967

7.  Forkhead box O1 targeting replication factor C subunit 2 expression promotes glioma temozolomide resistance and survival.

Authors:  Xingsheng Qiu; Guifeng Tan; Hao Wen; Lian Lian; Songhua Xiao
Journal:  Ann Transl Med       Date:  2021-04

8.  FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.

Authors:  K Levanon; S Sapoznik; K Bahar-Shany; H Brand; R Shapira-Frommer; J Korach; M S Hirsch; M H Roh; A Miron; J F Liu; N Vena; A H Ligon; S Fotheringham; D Bailey; R J Flavin; M J Birrer; R I Drapkin
Journal:  Oncogene       Date:  2013-09-30       Impact factor: 9.867

9.  Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade.

Authors:  Mingo Ming Ho Yung; David Wai Chan; Vincent Wing Sun Liu; Kwok-Ming Yao; Hextan Yuen-Sheung Ngan
Journal:  BMC Cancer       Date:  2013-07-03       Impact factor: 4.430

10.  Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma.

Authors:  Wen-Pin Su; Sen-Huei Hsu; Cheng-Kuei Wu; Song-Bin Chang; Yi-Ju Lin; Wen-Bin Yang; Jan-Jong Hung; Wen-Tai Chiu; Shun-Fen Tzeng; Yau-Lin Tseng; Jang-Yang Chang; Wu-Chou Su; Hungjiun Liaw
Journal:  Oncotarget       Date:  2014-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.